Loading cancer entity…
Loading cancer entity…
Clinical trials
792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05065021 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | unknown | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | unknown | Phase 2 | 80 | Guangxi Medical UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT03363867 | BEACON - ABC in Recurrent Platinum Resistant HGSOC(BEACON) | unknown | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03321188 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | unknown | Phase 2 | 20 | Andrea JewellOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT02125513 | Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer(GOGER-01) | unknown | Phase 2 | 129 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 30, 2022 | clinicaltrials |
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT03462212 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination(MITO25) | unknown | Phase 1 / Phase 2 | 290 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04556071 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer(AVANIRA3) | unknown | Phase 2 | 32 | Xiaoxiang ChenOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03188159 | Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer | unknown | Phase 2 | 36 | National University Hospital, SingaporeOTHER | 2 | Mar 29, 2018 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02435186 | p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | Phase 2 | 100 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | May 6, 2015 | clinicaltrials |
| NCT00003064 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 1 / Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00003560 | Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | unknown | Phase 2 | 40 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00004064 | Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 | 102 | AltaRexINDUSTRY | 2 | Nov 6, 2013 | clinicaltrials |
| NCT00005025 | Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | unknown | Phase 2 | — | John Stoddard Cancer Center at Iowa Methodist Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT01100372 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | unknown | Phase 2 | 154 | Medical University InnsbruckOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00305838 | CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen | unknown | Phase 2 | 200 | Mount Vernon Cancer Centre at Mount Vernon HospitalOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT00045461 | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer | unknown | Phase 2 / Phase 3 | 241 | Ludwig-Maximilians - University of MunichOTHER | 3 | Aug 7, 2013 | clinicaltrials |
| NCT01570582 | A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | unknown | Phase 2 | 314 | Korean Gynecologic Oncology GroupOTHER | 1 | Apr 4, 2012 | clinicaltrials |
| NCT00003160 | Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum | unknown | Phase 2 | 100 | TheradexINDUSTRY | 1 | Apr 20, 2011 | clinicaltrials |
| NCT00905658 | Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer | unknown | Phase 2 | 120 | Centre Oscar LambretOTHER | 1 | Jul 29, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Jan 17, 2024source: clinicaltrials